Search Result

Results for "

A549/T

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADAMTS (1) Akt (1) AMPK (2) Apoptosis (14) Bacterial (1) Bcl-2 Family (2) Calcium Channel (1) Caspase (3) CD28 (1) COX (1) Cyclin G-associated Kinase (GAK) (1) Cytochrome P450 (2) Drug Derivative (1) EGFR (8) Elastase (1) Endogenous Metabolite (1) ERK (1) GLUT (1) HDAC (2) Histone Methyltransferase (2) HSP (1) IFNAR (2) Interleukin Related (3) JAK (2) LAG-3 (1) MAP4K (1) Microtubule/Tubulin (5) P-glycoprotein (1) p38 MAPK (1) Parasite (1) PARP (1) PD-1/PD-L1 (2) Photosensitizer (1) PI3K (2) Proteasome (1) Reactive Oxygen Species (ROS) (2) ROS Kinase (1) Serotonin Transporter (1) STAT (2) TGF-beta/Smad (1) TNF Receptor (2) Topoisomerase (1) VEGFR (2) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (43) Infection (2) Inflammation/Immunology (5) Neurological Disease (1)

By Targets:

ADAMTS (1)

Akt (1)

AMPK (2)

Apoptosis (14)

Bacterial (1)

Bcl-2 Family (2)

Calcium Channel (1)

Caspase (3)

CD28 (1)

COX (1)

Cyclin G-associated Kinase (GAK) (1)

Cytochrome P450 (2)

Drug Derivative (1)

EGFR (8)

Elastase (1)

Endogenous Metabolite (1)

ERK (1)

GLUT (1)

HDAC (2)

Histone Methyltransferase (2)

HSP (1)

IFNAR (2)

Interleukin Related (3)

JAK (2)

LAG-3 (1)

MAP4K (1)

Microtubule/Tubulin (5)

P-glycoprotein (1)

p38 MAPK (1)

Parasite (1)

PARP (1)

PD-1/PD-L1 (2)

Photosensitizer (1)

PI3K (2)

Proteasome (1)

Reactive Oxygen Species (ROS) (2)

ROS Kinase (1)

Serotonin Transporter (1)

STAT (2)

TGF-beta/Smad (1)

TNF Receptor (2)

Topoisomerase (1)

VEGFR (2)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (43)

Infection (2)

Inflammation/Immunology (5)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P990957

Ficerafusp alfa BCA-101; FMAB2	EGFR TGF-beta/Smad	Inflammation/Immunology Cancer
Ficerafusp alfa (BCA-101) is a bispecific antibody targeting EGFR and TGFβ, with a K_d of 2.58 nM against EGFR and a K_d of 61.3 nM against TGFβ1. Ficerafusp alfa binds to EGFR, inhibits EGFR phosphorylation, blocks EGF-dependent cell proliferation, and mediates antibody-dependent cellular cytotoxicity against EGFR-positive tumor cells. Ficerafusp alfa sequesters TGFβ via its TGFβRII ECD domain, neutralizes the activity of TGFβ and TGFβ1, and blocks TGFβ-dependent processes, including epithelial-mesenchymal transition, cell invasion, and differentiation of inducible regulatory T cells. Ficerafusp alfa is applicable to research related to head and neck squamous cell carcinoma, advanced solid tumors, squamous non-small cell lung cancer, anal squamous cell carcinoma, colorectal cancer, and pancreatic cancer .

HY-P99345

Dostarlimab TSR-042; ANB-011; WBP-285	PD-1/PD-L1	Cancer
Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC₅₀s of 1.8 and 1.5 nM, respectively .

HY-119631

Nornidulin	Bacterial	Infection
Nornidulin is a depsidone originally isolated from A. nidulans that has antibacterial activity against M. tuberculosis and M. ranoe as well as antifungal activity against T. tonsurans and M. audouini. It also inhibits the growth of methicillin-resistant S. aureus (MRSA; MIC=2 μg/mL).2 Nornidulin has cytotoxic activity in MOLT-3 cells (IC₅₀=35.7 μM) but not HuCCA-1, HepG2, or A549 cells (IC₅₀s=>116.4 μM).

HY-124429

FQI1	ERK	Cancer
FQI1 is a Late SV40 Factor (LSF) inhibitor. FQI1 inhibits cell proliferation, with IC₅₀s of 3, 0.79, 6.3 μM for NIH/3T3, HeLa, A549 cells. FQI1 can be used for cancer research .

HY-155231

Neutrophil elastase inhibitor 4	Elastase	Cancer
Neutrophil elastase inhibitor 4 (compound 4f) is a competitive human neutrophil elastase (HNE) inhibitor (IC₅₀: 42.30 nM, K_i: 8.04 nM). Neutrophil elastase inhibitor 4 induces T47D cell apoptosis. Neutrophil elastase inhibitor 4 inhibits cell proliferation with IC₅₀s of 21.25, 34.17, 29.93, 99.11 nM for T47D, RPMI 8226, A549, and HSF cells .

HY-130723A

AMPK activator 2 hydrochloride	AMPK	Cancer
AMPK activator 2 (compound 7a) hydrochloride, a fluorine-containing proguanil derivative, up-regulates AMPK signal pathway and downregulates mTOR/4EBP1/p70S6K. AMPK activator 2 hydrochloride inhibits proliferation and migration of human cancer cell lines (UMUC3, T24, A549) .

HY-101450

PF-6274484	EGFR	Cancer
PF-6274484 is a potent EGFR inhibitor with K_is of 0.14 nM and 0.18 nM for EGFR-L858R/T790M and WT EGFR, respectively. PF-6274484 inhibits EGFR-L858R/T790M autophosphorylation in H1975 tumor cells and EGFR WT in A549 tumor cells with IC₅₀s of 6.6 and 5.8 nM, respectively .

HY-172394

ZSNI-21	HDAC ADAMTS Apoptosis Bcl-2 Family Cyclin G-associated Kinase (GAK)	Cancer
ZSNI-21 is a ADAM17/HDAC2 inhibitor with ADAM17 IC₅₀ 0.939 μM and HDAC2 IC₅₀ 0.844 μM. ZSNI-21 regulates the expression of apoptosis-related proteins (Bax, Bcl-2) and Cyclin D1, and induces apoptosis.. ZSNI-21 can be used for the research of hepatocellular carcinoma, breast cancer, and non-small cell lung cancer .

HY-155050

PRMT5-IN-31	Apoptosis Histone Methyltransferase	Cancer
PRMT5-IN-31 (Compound 3m) is a selective PRMT5 inhibitor (IC₅₀: 0.31 μM). PRMT5-IN-31 up-regulates hnRNP E1 protein level. PRMT5-IN-31 occupies the substrate site of PRMT5 and forms essential interactions with amino acid residues. PRMT5-IN-31 has antiproliferative effects against A549 cells by inducing apoptosis and inhibiting cell migration. PRMT5-IN-31 has high metabolic stability on human liver microsomes (T_1/2: 132.4 min) .

HY-175874

Tubulin-IN-55	Microtubule/Tubulin PI3K Akt Apoptosis	Cancer
Tubulin-IN-55 is a tubulin inhibitor. Tubulin-IN-55 disrupts the PI3K/Akt signaling pathway in cancer cells. Tubulin-IN-55 exerts broad-spectrum anti-proliferative activity against multiple tumor cells (HeLa, HCT116, 4T1, A549, H1299, MDA-MB231). Tubulin-IN-55 induces G2/M phase arrest and apoptosis, and inhibits tumor cell migration/invasion in cancer cells. Tubulin-IN-55 demonstrates potent antitumor efficacy in orthotopic autologous transplantation mice. Tubulin-IN-55 can be used for the study of cancer .

HY-173489

Wnt/β-catenin-IN-5	Wnt β-catenin	Cancer
Wnt/β-catenin-IN-5 (compound 19T) is a Wnt/β-catenin signaling pathway inhibitor. Wnt/β-catenin-IN-5 inhibits HCT 116, SW480, and A549 cells activity with IC₅₀s of 3.05, 3.27 and 34.91 μM, respectively .

HY-159123

KHK-6	MAP4K	Cancer
KHK-6 is an inhibitor for serine/threonine kinase hematopoietic progenitor kinase 1 (HPK 1) with an IC₅₀ of 20 nM. KHK-6 enhances CD3/CD28-induced cytokine production, enhances CD69, CD25 and HLA-DR markers on CD4+ and CD8+ T cells, and enhances T cell-mediated killing activity of SKOV3 and A549 cells .

HY-170910

Hsp90-IN-39	HSP	Cancer
Hsp90-IN-39 (Compound 16t) is a HSP90 inhibitor with notable selectivity for the HSP90α isoform. Hsp90-IN-39 demonstrates significant antiproliferative activity in various cancer cell lines, including MCF-7, HCT116, SKBr3, K562, and A549. Hsp90-IN-39 holds potential for cancer research .

HY-170568

Tubulin polymerization-IN-73	Microtubule/Tubulin Apoptosis	Cancer
Tubulin polymerization-IN-73 (Compound 37) is an inhibitor for microtubule polymerization with an IC₅₀ of 1.8 μM. Tubulin polymerization-IN-73 arrests the cell cycle at G2/M phase, induces apoptosis in A549 cell, inhibits the proliferation of A549 WT and A549/T resistant cell with IC₅₀ of 0.023 μM and 0.057 μM. Tubulin polymerization-IN-73 exhibits antitumor efficacy in mouse model .

HY-176051

Rapaglutin E RgE	GLUT	Cancer
Rapaglutin E (RgE) is a glucose transporter (GLUT) inhibitor. Rapaglutin E exhibits dose-dependent inhibition of [ ³H]-2DG uptake in A549, Jurkat T, PANC10.05, and RBC, with IC₅₀ values 8.9 nM, 3.1 nM, 35.5 nM, 74.2 nM. Rapaglutin E inhibits cell proliferation in A549, PANC10.05, HeLa, Jurkat T, and HEK293T cells .

HY-165114

6-Hydroxyramulosin	Endogenous Metabolite	Cancer
6-Hydroxyramulosin is a fungal metabolite with antiancer effects. 6-Hydroxyramulosin shows cytotoxic effects against A549 and T24, showing IC₅₀ values of 14.2 µg/mL and 15.3 µg/mL, respectively .

HY-172112

VEGFR-2-IN-64	VEGFR Apoptosis	Cancer
VEGFR-2-IN-64 (Compound 28) is the inhibitor for VEGFR2 with IC₅₀ of 27.8 nM. VEGFR-2-IN-64 inhibits the proliferation of cancer cell A549, T-47D and Caco-2, exhibits anti-migration and anti-cloning activities in cell T-47D, induces apoptosis in T-47D .

HY-129765

Thiobenzanilide 63T	Reactive Oxygen Species (ROS)	Cancer
Thiobenzanilide 63T (63T) is a small molecule that selectively induces cancer cell death in a caspase-independent pathway. Thiobenzanilide 63T induces reactive oxygen species and lipid peroxidation. Thiobenzanilide 63T demonstrates strong cytotoxic activity against a lung-derived cancer cell line. Thiobenzanilide 63T decreases the expression of heme oxygenase (HO-1) in A549 cells .

HY-162885

YSY01A	Proteasome JAK STAT Interleukin Related	Cancer
YSY01A is a proteasome inhibitor that can suppress cancer cell survival by inducing apoptosis (Apoptosis). Its IC₅₀ values are 51.0 nM for HEK293T, 9.2 nM for A549, 5.2 nM for MCF-7, 8.9 nM for MGC-803, and 35.4 nM for PC-3M cells. Additionally, YSY01A eliminates constitutive STAT3 signaling by downregulating gp130 and JAK2 in human A549 lung cancer cells. YSY01A holds promise for research in the field of cancer therapy .

HY-158090

Triptolide palmitate	Drug Derivative	Cancer
Triptolide palmitate is the derivative of Triptolide (HY-32735). Triptolide palmitate exhibits cytotoxicity against cancer cell MCF-7 and A549, with IC₅₀ of 7.5 and 6.4 μM. Triptolide palmitate exhibits a half-time T_1/2 of 50.4 min in Sprague Dawley rats. Triptolide palmitate can be utilizd as drug carrier .

HY-147862

EGFR-IN-62	EGFR Apoptosis	Cancer
EGFR-IN-62 (compound 9h) is a potent and reversible EGFR kinase inhibitor, with IC₅₀ values of 10 nM (L858R/T790 M), 29 nM (WT), and 242 nM (L858R/T790 M/C797S), respectively. EGFR-IN-62 shows antiproliferative activity against A549 and H1975 cell lines, with IC₅₀ values of 2.53 and 1.56 μM, respectively. EGFR-IN-62 induces dose-dependent apoptosis process, G1/G0-phase arrestation, and the inhibition of motility on A549 and/or H1975 cell lines .

HY-157398

EGFR T790M/L858R-IN-3	EGFR	Cancer
EGFR T790M/L858R-IN-3 (compound B1) is a EGFR ^L858R/T790M inhibitor with IC₅₀ value of 13?nM. EGFR T790M/L858R-IN-3 shows anti-tumour activity in H1975 cells with an IC₅₀ value of 0.087 μΜ. EGFR T790M/L858R-IN-3 inhibits cell migration in A549 cells and induces apoptosis in H1975 cells .

HY-162342

Topoisomerase I inhibitor 14	Topoisomerase	Cancer
Topoisomerase I inhibitor 14 (Compound 4h) is an inhibitor for Topoisomerase I. Topoisomerase I inhibitor 14 inhibits proliferation of A549 and C6 with IC₅₀s of 4.56 μM and 13.17 μM, without significant toxicity in healthy cells NIH3T3 (IC₅₀ is 74.44 μM), which exhibits anticancer potency .

HY-130723

AMPK activator 2	AMPK	Cancer
AMPK activator 2 (compound 7a), a fluorine-containing proguanil derivative, up-regulates AMPK signal pathway and downregulates mTOR/4EBP1/p70S6K. AMPK activator 2 inhibits proliferation and migration of human cancer cell lines (UMUC3, T24, A549) .

HY-159176

Antitumor agent-183	Cytochrome P450	Cancer
Antitumor agent-183 (compound 3f) has antitumor activity with metabolic stability. Antitumor agent-183 inhibits cancer cell growth, with IC₅₀s less than 5 nM for A549, HCT116, and HS578T cells. The albumin-bound nanoparticle formulation of Antitumor agent-183 has prolonged retention in the tumor tissues .

HY-147860

EGFR-IN-61	EGFR	Cancer
EGFR-IN-61 (compound 22a) is a potent EGFR kinase inhibitor, with IC₅₀ values of 42 nM (L858R/T790 M), 137 nM (L858R/T790 M/C797S), and 743 nM (WT), respectively. EGFR-IN-61 shows antiproliferative activity against A549 and H1975 cell lines, with IC₅₀ values of 2.14 and 1.82 μM, respectively .

HY-171038

STAT3-IN-39	STAT	Inflammation/Immunology
STAT3-IN-39 (compound 10K) is an orally active STAT3 inhibitor that exhibits excellent inhibitory activity against STAT3 phosphorylation, with an IC₅₀ of 0.47 μM in NIH-3T3 cells. STAT3-IN-39 inhibits the TGF-β1-induced fibrotic response and blocks the epithelial-mesenchymal transition in A549. STAT3-IN-39 can be utilized in research related to idiopathic pulmonary fibrosis .

HY-146461

Anticancer agent 58	Apoptosis Caspase ROS Kinase	Cancer
Anticancer agent 58 (compound 16) has inhibitory activity against kinds of cancer cell lines, especially in A549 and T24 with IC₅₀s of 0.6 μM and 0.7 μM, respectively. Anticancer agent 58 induces apoptosis by activating caspase 3/8/9 activity, and induces an increase of Ca ²⁺ and ROS in cancer cells. Anticancer agent 58 significantly decreases mitochondrial membrane potential. Anticancer agent 58 can suppress tumor growth in T24 mouse xenograft model .

HY-147708

T-Type calcium channel inhibitor 2	Calcium Channel	Cancer
T-Type calcium channel inhibitor 2 (compound 6g) is a potent T-type calcium channel inhibitor with IC₅₀s of 31.0, 83.1, 69.3 µM for Cav3.1 (α1G), Cav3.2 (α1H), Cav3.3 (α1I) (α1H), respectively. T-Type calcium channel inhibitor 2 shows cytotoxicity for A549, HCT-116 cells with IC₅₀s of 5.0, 6.4 µM, respectively .

HY-N15636

Coccinine (-)-Coccinine	Serotonin Transporter P-glycoprotein	Neurological Disease Cancer
Coccinine ((-)-Coccinine) is a weak inhibitor of SERT (IC₅₀: 196.3 μM; K_i: 106.8 μM) and P-gp (IC₅₀: 0.96 mM). Coccinine exhibits significant anti-tumor activity against various cancer cell lines, such as breast cancer (MCF7, Hs578T, MDA-MB-231), colon cancer (HCT-15), and lung cancer (A549). Coccinine can be used in the research of tumors and neurological diseases .

HY-175297

EGFR T790M/VEGFR-2-IN-1	VEGFR EGFR	Cancer
EGFR T790M/VEGFR-2-IN-1 (Compound 6) is a dual EGFR T790M mutant (IC₅₀=0.26 μM) and VEGFR-2 (IC₅₀=0.95 μM) inhibitor. EGFR T790M/VEGFR-2-IN-1 blocks tumor cell proliferation and angiogenesis signaling pathways. EGFR T790M/VEGFR-2-IN-1 exhibits potent cytotoxicity against multiple cancer cell lines (HCT116, MCF-7, HepG2, A549; IC₅₀=5.35-9.90 μM). EGFR T790M/VEGFR-2-IN-1 is promising for research of non-small cell lung cancer and solid tumors .

HY-161825

Tubulin polymerization-IN-66	Microtubule/Tubulin Apoptosis	Cancer
Tubulin polymerization-IN-66 (Compound 13) inhibits colony formation and tubulin polymerization. Tubulin polymerization-IN-66 induces apoptosis. Tubulin polymerization-IN-66 inhibits cell viability of A549, A2780, SKOV3, HCC827 cells, with IC₅₀s of 0.84, 0.38, 0.31, 0.34 nM respectively. Tubulin polymerization-IN-66 is also active against the Paclitaxel (HY-B0015)-resistant cancer cell line A2780/T and its parental cell line A2780 .

HY-155051

Antiproliferative agent-25	Apoptosis Histone Methyltransferase	Cancer
Antiproliferative agent-25 (Compound 3s4) is a selective PRMT5 inhibitor (IC₅₀: 0.11 μM). Antiproliferative agent-25 up-regulates hnRNP E1 protein level. Antiproliferative agent-25 forms H-bond interactions with SAM and E444 residue of PRMT5. Antiproliferative agent-25 has antiproliferative effects against A549 cells by inducing apoptosis and inhibiting cell migration. Antiproliferative agent-25 has high clearances with T_1/2 of only 21.8 and 4.7 min in human and rat liver microsomes .

HY-136727A

Ac-LEVD-CHO TFA	Caspase Apoptosis	Cancer
Ac-LEVD-CHO (TFA) is an inhibitor of caspase-4. Ac-LEVD-CHO (TFA) can inhibit the expression and secretion of IL-1α expression as well as the activation of caspase-4 induced by the T. denticola periodontal pathogen surface protein Td92 in human gingival fibroblasts. Ac-LEVD-CHO (TFA) can also reduce the apoptosis due to the expression of the dominant negative adenoviral RNA-dependent protein kinase in A549 and PC3 cancer cell lines .

HY-170438

EGFR-IN-139	EGFR	Cancer
EGFR-IN-139 (compound PD 18) is an epidermal growth factor receptor (EGFR) inhibitor, with IC₅₀s of 12.88 (wild type), 10.84 (L858R/T790M), 42.68 (L858R/T790M/C797S) nM, respectively. EGFR-IN-139 displays strong anticancer activity against A549 and H1975 cancer cell lines, which are highly expressed EGFR. EGFR-IN-139 has a strong selectivity to cancer cells. EGFR-IN-139 can be used for nonsmall cell lung cancer (NSCLC) research_[1].

HY-161641

Tubulin polymerization-IN-62	Microtubule/Tubulin	Cancer
Tubulin polymerization-IN-62 (Compound 14b) is an inhibitor for microtubule polymerization (IC₅₀ is 7.5 μM) and a degrader for α- and β-tubulin. Tubulin polymerization-IN-62 inhibits proliferation of cancer cells MCF-7, A549 and HCT-116, with IC₅₀ of 32, 60 and 29 nM, respectively. Tubulin polymerization-IN-62 arrests the cell cycle at G2/M phase, inhibits the migration of MCF-7. Tubulin polymerization-IN-62 exhibits antitumor efficacy with a tumor growth inhibition rate (TGI) of 74.27% in 4T1 homograft mouse model .

HY-174425

CYP1B1-IN-9	Cytochrome P450	Cancer
CYP1B1-IN-9 is a highly selective and competitive CYP1B1 Inhibitor with IC₅₀ values of 1.48 nM, > 100 μM, and > 80 μM for CYP1B1, CYP1A1, and CYP1A2, respectively. CYP1B1-IN-9 significantly inhibits the migration and invasion of A549/T cells. CYP1B1-IN-9 has the ability to resensitize Paclitaxel (HY-B0015)-resistant cells, and good metabolic stability and safety, and shows favorable pharmacokinetic parameters. CYP1B1-IN-9 can be used for the study of tumor-drug resistance .

HY-170932

EGFR/COX-2-IN-1	EGFR COX Apoptosis	Cancer
EGFR/COX-2-IN-1 is an EGFR/COX-2 inhibitor. EGFR/COX-2-IN-1 inhibits EGFR ^WT, EGFR ^T790M, COX-1 and COX-2 with IC₅₀s of 0.12, 0.076, 20.1 and 1.52 μM respectively. EGFR/COX-2-IN-1 inhibits and with IC₅₀s of , respectively. EGFR/COX-2-IN-1 inhibits MCF-7, HT-29 and A-549 with IC₅₀s of 1.20, 5.14 and 14.81 μM, respectively. EGFR/COX-2-IN-1 displays Apoptosis induction by up-regulating Bax and down-regulating Bcl-2 protein levels. EGFR/COX-2-IN-1 results in a significant increase in the percentage of cells at the G2/M in MFC-7 cells. EGFR/COX-2-IN-1 exhibits broad-spectrum antitumor effects .

HY-144395

HDAC6-IN-4	HDAC Apoptosis	Inflammation/Immunology Cancer
HDAC6-IN-4 (C10) is a potent, orally active and highly selective HDAC6 inhibitor with an IC₅₀ value of 23 nM. HDAC6-IN-4 induces cancer cells apoptosis and shows significant antitumor efficacy, without obvious toxicity .

HY-170883

Type-I/-II Photosensitizer-1	Photosensitizer	Cancer
Type-I/-II Photosensitizer-1 (compound 8b) is a photosensitizer with anticancer activity. Type-I/-II Photosensitizer-1 exhibits significant phototoxicity against both A549 and 4T1 tumor cells. Type-I/-II Photosensitizer-1 shows a strong oxygen-independent antitumor effect under laser irradiation (IC₅₀=1.50-1.76 μM) .

HY-179451

Apoptosis inducer 53	Apoptosis p38 MAPK Parasite	Infection Inflammation/Immunology Cancer
Apoptosis inducer 53 is an apoptosis inducer. Apoptosis inducer 53 can inhibit proliferation of human tumor cell lines (A549, HeLa, SW1573, T-47D, WiDr) with GI₅₀ values of 2.5-9.1 μM. Apoptosis inducer 53 can induce cancer cells apoptosis and reduce colony formation. Apoptosis inducer 53 can activate p38α MAPK signaling and exerts anti-inflammatory effect. Apoptosis inducer 53 also shows anti-Leishmania donovani activity. Apoptosis inducer 53 can be used for the researches of cancer, infection and inflammation .

HY-181663

PJ27	PD-1/PD-L1 JAK	Cancer
PJ27 is a dual PD-1/PD-L1/JAK1 inhibitor, with an IC₅₀ of 414 nM against PD-1/PD-L1, an IC₅₀ of 786 nM against JAK1, a K_a of 294 nM for human PD-1/PD-L1, and a K_a of 473 nM for murine PD-1/PD-L1. PJ27 promotes the infiltration of CD3 ⁺CD8 ⁺ and CD3 ⁺CD4 ⁺ cells into the tumor microenvironment and exerts a significant immune activation effect. PJ27 inhibits tumor growth in a dose-dependent manner in the LLC lung cancer mouse model. PJ27 is applicable to relevant research on lung cancer .

HY-181685

LAGi-DEL	LAG-3 TNF Receptor	Cancer
LAGi-DEL is a LAG-3 inhibitor, with K_d values of 97.33 nM and 271 nM in surface plasmon resonance (SPR) assay and microscale thermophoresis (MST) assay, respectively. LAGi-DEL blocks the LAG-3/MHC-II interaction, with an EC₅₀ of 138 nM. LAGi-DEL restores T cell activation, enhances IFN-γ secretion and promotes immune-mediated cytotoxicity. LAGi-DEL can be used in the research of acute myeloid leukemia, lung cancer and melanoma .

HY-181673

ICD inducer-2	Microtubule/Tubulin Apoptosis Bcl-2 Family Caspase PARP	Cancer
ICD inducer-2 is a immunogenic cell death inducer. ICD inducer-2 binds to the colchicine binding site on tubulin to inhibit tubulin polymerization. ICD inducer-2 exhibits broad-spectrum antiproliferative activity across multiple cancer cell lines. ICD inducer-2 inhibits cells migration, causes G2/M phase and induces apoptosis. ICD inducer-2 promotes infiltration of CD4+ and CD8+ T cells into the tumor microenvironment. ICD inducer-2 downregulates antiapoptotic protein Bcl-2, upregulates proapoptotic proteins Bax and Bim-1, and increases cleaved caspase 3, cleaved caspase 9, and cleaved PARP levels. ICD inducer-2 overcomes paclitaxel resistance in xenograft models and achieves tumor growth inhibition. ICD inducer-2 can be used for the research of cancer, such as lung carcinoma .

HY-181507

CD28-IN-3	CD28 IFNAR TNF Receptor Interleukin Related	Cancer
CD28-IN-3 is a CD28 inhibitor with an IC₅₀ of 7.80 μM and a Kd of 52.45 μM. CD28-IN-3 selectively blocks the CD28-B7 interaction, thereby inhibiting CD28-mediated costimulation. CD28-IN-3 suppresses the production of proinflammatory cytokines IFN-γ, IL-2 and TNF-α. CD28-IN-3 can be used in the research of checkpoint-resistant cancers .

HY-182693

CPL302-253	PI3K IFNAR Reactive Oxygen Species (ROS) Interleukin Related	Inflammation/Immunology
CPL302-253 is a PI3Kδ inhibitor with an IC₅₀ of 12.20 nM and a human K_d of 0.85 nM. CPL302-253 functionally regulates PI3Kδ activity, blocks the production of IFNγ, IL-33 and ROS in immune cells, and affects immune function. CPL302-253 blocks the progression of asthma-inducing inflammatory responses in a mouse model of asthma. CPL302-253 can be used for research related to asthma .

Cat. No.	Product Name	Target	Research Area